Shareholders of Dr Reddys Laboratories approved a final dividend of ₹8 per equity share for the financial year ended March 31, 2026, during its 42nd Annual General Meeting held on July 23, 2026. The virtual meeting, conducted via Video Conferencing and Other Audio-Visual Means (OAVM), also witnessed the re-appointment of Chairman K Satish Reddy and the appointment of Deloitte Haskins & Sells LLP as statutory auditors for a five-year term. The approval of these key governance and shareholder return measures underscores continued investor confidence in the company’s leadership and financial stewardship.

The meeting commenced at 11:00 AM IST with 86 members holding 22,25,59,764 shares in attendance, satisfying the quorum requirements under Article 70 of the Articles of Association. Chairman K Satish Reddy presided over the proceedings, which were scrutinized by Atul Mehta of Mehta & Mehta, Company Secretaries. In compliance with Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, voting was conducted through remote e-voting from July 19 to July 22, 2026, and via electronic voting during the AGM. All seven resolutions on the agenda were declared passed by the requisite majority.

Key Resolutions Passed

The Board of Directors sought shareholder approval for several ordinary and special resolutions. The dividend declaration received near-unanimous support, with 99.99% of votes cast in favor. Similarly, the adoption of the audited financial statements for FY26 passed with 99.99% approval. The re-appointment of K Satish Reddy, who retires by rotation, secured 99.38% support.

Governance and Auditor Appointments

The company appointed M/s. Deloitte Haskins & Sells LLP as its statutory auditors for a period of five consecutive years, commencing from the conclusion of the 42nd AGM till the conclusion of the 47th AGM. This resolution passed with 99.98% support. Additionally, the remuneration payable to cost auditors M/s. Sagar & Associates for the financial year ending March 31, 2027, was ratified with 99.99% approval.

In terms of board composition, shareholders approved the re-appointment of Dr. K P Krishnan as an Independent Director for a second term of five years, effective from January 7, 2027, to January 6, 2032. The resolution received 97.27% support. The company also appointed Mr. Srikanth Velamakanni as an Independent Director for a five-year term, effective from July 1, 2026, to June 30, 2031. This special resolution passed with 91.35% of votes in favor.

What the Numbers Show

The voting patterns reveal strong institutional alignment with management proposals, particularly on financial and audit matters. The promoter group, holding 22,23,05,640 shares, voted unanimously in favor of all resolutions. Public institutions accounted for approximately 91% of the total votes polled, indicating high engagement from large investors. While the appointment of Srikanth Velamakanni faced notable dissent (8.65% against), it still comfortably met the three-to-one majority requirement for special resolutions, reflecting broad-based acceptance of the board’s governance strategy.

Dr. Reddy's Laboratories Ltd. announced the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, effective July 22, 2026. The Board of Directors approved this appointment pursuant to the recommendation of the Nomination, Governance and Compensation Committee. Additionally, the Board approved the appointment of M/s Deloitte Haskins & Sells LLP as the Independent Registered Public Accounting Firm for auditing financial statements to be included in the Annual Report on Form 20-F and reviewing interim financial statements filed with the U.S. Securities and Exchange Commission.

Management Appointments

Dr. Sridevi Khambhampaty has been inducted as a Member of the Management Council. She is an accomplished biopharmaceutical leader with over two decades of experience spanning Biologics R&D, Quality, and Business leadership. Most recently, she served as the CEO of Shilpa Biologics. Prior to this, she held senior leadership roles at Syngene International and Intas Biopharma. In her previous stint at Dr Reddy's, she led teams in Product Development and Quality Control at Biologics. She holds a PhD in Biological Sciences from NCBS (TIFR) and completed her postdoctoral research at Stanford University School of Medicine.

Auditor Appointment

The appointment of M/s Deloitte Haskins & Sells LLP as the Independent Registered Public Accounting Firm aligns with its earlier appointment as Statutory Auditors for a term of five consecutive years, commencing from the conclusion of the 42nd AGM till the conclusion of the 47th AGM, subject to shareholder approval. The firm, registered with the Institute of Chartered Accountants of India (Registration No. 117366W/W-100018), will audit financial statements for the Annual Report on Form 20-F and review interim financial statements filed with the U.S. Securities and Exchange Commission on Form 6-K.